Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Karyopharm Therapeutics Inc. (KPTI)

4.94   0.03 (0.61%) 11-25 13:00
Open: 4.89 Pre. Close: 4.91
High: 4.96 Low: 4.8
Volume: 401,888 Market Cap: 401(M)

Technical analysis

as of: 2022-11-28 8:49:32 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.22     One year: 6.97
Support: Support1: 4.3    Support2: 3.57
Resistance: Resistance1: 5.33    Resistance2: 5.96
Pivot: 5.2
Moving Average: MA(5): 4.86     MA(20): 5.09
MA(100): 5.01     MA(250): 6.23
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 34.1     %D(3): 31.4
RSI: RSI(14): 47
52-week: High: 14.72  Low: 4
Average Vol(K): 3-Month: 1,774 (K)  10-Days: 1,452 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KPTI ] has closed above bottom band by 30.0%. Bollinger Bands are 2.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.97 - 4.99 4.99 - 5.01
Low: 4.75 - 4.77 4.77 - 4.79
Close: 4.91 - 4.94 4.94 - 4.98

Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Headline News

Mon, 21 Nov 2022
Merck deal for Imago is positive for Karyopharm, Prelude – Barclays (NASDAQ:KPTI) - Seeking Alpha

Tue, 08 Nov 2022
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) CEO Richard A. Paulson Sells 3493 Shares - MarketBeat

Fri, 04 Nov 2022
Karyopharm Therapeutics (KPTI) Q3 2022 Earnings Call Transcript - The Motley Fool

Thu, 03 Nov 2022
2022-11-03 | NDAQ:KPTI | Press Release | Karyopharm Therapeutics Inc. - Stockhouse

Thu, 03 Nov 2022
Karyopharm Therapeutics GAAP EPS -$0.45 beats by $0.10, revenue $36.1M beats by $1.27M - Seeking Alpha

Thu, 03 Nov 2022
Karyopharm Therapeutics Inc. (KPTI) Q3 2022 Earnings Call Transcript - Seeking Alpha

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 81 (M)
Shares Float 74 (M)
% Held by Insiders 8.7 (%)
% Held by Institutions 87.5 (%)
Shares Short 13,520 (K)
Shares Short P.Month 13,440 (K)

Stock Financials

EPS -1.43
EPS Est Next Qtl -0.62
EPS Est This Year -2.62
EPS Est Next Year -2.31
Book Value (p.s.) -1.74
Profit Margin (%) -35.3
Operating Margin (%) -24.6
Return on Assets (ttm) -15.9
Return on Equity (ttm) 0
Qtrly Rev. Growth -4.1
Gross Profit (p.s.) 0.7
Sales Per Share 3.07
EBITDA (p.s.) -0.75
Qtrly Earnings Growth 0
Operating Cash Flow -97 (M)
Levered Free Cash Flow -59 (M)

Stock Valuations

PE Ratio -3.48
PEG Ratio 0
Price to Book value -2.86
Price to Sales 1.6
Price to Cash Flow -4.13

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.